These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22028816)

  • 1. Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model.
    Kim SK; Yun SJ; Kim J; Lee OJ; Bae SC; Kim WJ
    PLoS One; 2011; 6(10):e26131. PubMed ID: 22028816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
    Grubbs CJ; Lubet RA; Koki AT; Leahy KM; Masferrer JL; Steele VE; Kelloff GJ; Hill DL; Seibert K
    Cancer Res; 2000 Oct; 60(20):5599-602. PubMed ID: 11059745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular credentialing of rodent bladder carcinogenesis models.
    Williams PD; Lee JK; Theodorescu D
    Neoplasia; 2008 Aug; 10(8):838-46. PubMed ID: 18670642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
    PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
    Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
    Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.
    Shiina H; Igawa M; Urakami S; Shigeno K; Yoneda T; Terashima M; Deguchi M; Ribeiro-Filho L; Dahiya R
    Cancer Res; 2001 Oct; 61(19):7101-9. PubMed ID: 11585741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.
    Tyagi A; Raina K; Singh RP; Gu M; Agarwal C; Harrison G; Glode LM; Agarwal R
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3248-55. PubMed ID: 18089718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin.
    Lubet RA; Huebner K; Fong LY; Altieri DC; Steele VE; Kopelovich L; Kavanaugh C; Juliana MM; Soong SJ; Grubbs CJ
    Carcinogenesis; 2005 Mar; 26(3):571-8. PubMed ID: 15591090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of differently expressed genes in chemical carcinogen-induced rat bladder cancers.
    Chen G; Chan FL; Zhang X; Chan PS
    J Huazhong Univ Sci Technolog Med Sci; 2009 Apr; 29(2):220-6. PubMed ID: 19399409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Elkin M; Ayesh S; Schneider T; de Groot N; Hochberg A; Ariel I
    Carcinogenesis; 1998 Dec; 19(12):2095-9. PubMed ID: 9886562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
    Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis.
    Chuang JJ; Dai YC; Lin YL; Chen YY; Lin WH; Chan HL; Liu YW
    Toxicol Appl Pharmacol; 2014 Sep; 279(3):322-330. PubMed ID: 24998975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
    Degoricija M; Korac-Prlic J; Vilovic K; Ivanisevic T; Haupt B; Palada V; Petkovic M; Karaman I; Terzic J
    J Transl Med; 2019 Nov; 17(1):394. PubMed ID: 31779626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis.
    He Z; Kosinska W; Zhao ZL; Wu XR; Guttenplan JB
    Mutat Res; 2012 Feb; 742(1-2):92-5. PubMed ID: 22155125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive effect of 1,4-phenylene diisothiocyanate on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.
    Sugie S; Vinh PQ; Rahman KM; Ushida J; Kohno H; Suzuki R; Hara A; Quang le B; Tanaka T; Mori H
    Int J Cancer; 2005 Nov; 117(4):524-30. PubMed ID: 15929075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl) nitrosamine as the basis for urothelial cell carcinogenesis." He Z, Kosinska W, Zhao ZL, Wu XR, Guttenplan JB, Department of Basic Science, New York University Dental College, NY, USA.: Mutat Res 2012;742(1-2):92-5 [Epub 2011 Dec 4].
    Scherr DS
    Urol Oncol; 2014 Feb; 32(2):214. PubMed ID: 24445298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele.
    Ozaki K; Sukata T; Yamamoto S; Uwagawa S; Seki T; Kawasaki H; Yoshitake A; Wanibuchi H; Koide A; Mori Y; Fukushima S
    Cancer Res; 1998 Sep; 58(17):3806-11. PubMed ID: 9731488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: BBN as an urothelial carcinogen.
    Vasconcelos-Nóbrega C; Colaço A; Lopes C; Oliveira PA
    In Vivo; 2012; 26(4):727-39. PubMed ID: 22773588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survivin gene signature predicts aggressive tumor behavior.
    Salz W; Eisenberg D; Plescia J; Garlick DS; Weiss RM; Wu XR; Sun TT; Altieri DC
    Cancer Res; 2005 May; 65(9):3531-4. PubMed ID: 15867343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
    Lubet RA; Fischer SM; Steele VE; Juliana MM; Desmond R; Grubbs CJ
    Int J Cancer; 2008 Nov; 123(10):2254-9. PubMed ID: 18712722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.